We assessed the effects of low doses of BTX-A injected into the rat whisker pad (3.5 U/kg) or into the sensory trigeminal ganglion (1 U/kg) on formalin-induced facial pain. Presented data provide the first evidence that axonal transport of BTX-A, obligatory for its antinociceptive effects, occurs via sensory neurons and is directed to sensory nociceptive nuclei in the CNS.
Abbreviations: BTX-A, botulinum toxin A; SNAP-25, synaptosomal-associated protein 25; i.g., intraganglionic (in trigeminal ganglion); SDS-PAGE, sodium dodecyl sulfatepolyacrylamide gel electrophoresis; CGRP, calcitonin gene-related peptide.
Apart from its well known therapeutic use in muscular hyperactivity and certain autonomic disorders (Ward et al., 2006 , Truong et al., 2009 , botulinum toxin A (BTX-A) was recently registered for migraine treatment (Dodick et al., 2010) . Besides migraine, its beneficial effects not associated with cholinergic neurotransmission were reported in cluster headache, neuropathic pain, joint pain, back pain, etc (Querama et al., 2010) . It was suggested that BTX-A, similarly to its activity in cholinergic neurons, inhibits the local neurotransmitter release from sensory nerve endings by peripheral SNAP-25 (Synaptosomal Associated Protein of 25 kDa) cleavage (Cui et al., 2004; Aoki, 2005) .
Recent studies of rat "mirror pain" (muscular hyperalgesia) and polyneuropathy models (paclitaxel-induced polyneuropathy, diabetic neuropathy) demonstrated bilateral effects following unilateral BTX-A injection (Bach-Rojecky and Lacković, 2009; Favre-Guilmard et al., 2009; Bach-Rojecky et al., 2010) . Obviously, such effects cannot be explained only by local action on the sensory nerve endings adjacent to the site of injection. Importantly, BTX-A effects were prevented by colchicine-induced blockage of axonal transport in the sciatic nerve, suggesting that retrograde axonal transport of BTX-A is necessary for its antinociceptive action (Bach-Rojecky and Lacković, 2009 ). However, neurons involved in axonal transport are unknown as well as the destination of transported BTX-A. So far, axonal transport of BTX-A from periphery to the CNS was demonstrated only in motoneurons (Antonucci et al., 2008) , but with unknown functional significance.
Aims of this study were to investigate a.) in which neurons does BTX-A axonal transport, essential for its antinociceptive effects, take place, and b.) to locate the destination of axonally transported BTX-A. Therefore, we examined the effects of low doses of BTX-A injected into the whisker pad or trigeminal ganglion on formalin-induced orofacial pain, and used intraganglionic colchicine to prevent the axonal transport in trigeminal sensory neurons. To investigate the possible site of BTX-A antinociceptive action we employed immunolabeling of BTX-A-truncated SNAP-25 in trigeminal nucleus caudalis.
EXPERIMENTAL PROCEDURES

Animals
Male Wistar rats (University of Zagreb School of Medicine, Croatia), weighing 300-400 g, kept on 12 h/12h light and dark cycle, were used in all experiments. The experiments were conducted according to the European Communities Council Directive (86/609/EEC) and recommendations of the International Association for the Study of Pain (Zimmerman, 1983) .
All efforts were made to reduce the number of animals used and to reduce their suffering.
Animal procedures were approved by the Ethical Committee of University of Zagreb School of Medicine (permit No. 07-76/2005-43) .
BTX-A injections
For peripheral administration, conscious, restrained rats were injected unilaterally with 30 µl of saline-diluted BTX-A 3.5 U/kg (Botox®, Allergan Inc., Irvine, CA, USA) into the whisker pad tissue using a 27 1 / 2 -gauge needle. 3.5 U/kg dose was chosen based on previous experiments by Cui et al., (2004) and from our laboratory . For intraganglionic (i.g.) injections, animals were anesthetized with chloral hydrate (Sigma, St. Louis, MO, USA; 300 mg/kg i.p.). Trigeminal ganglion was 6 injected as described by Neubert et al. (2005) . In brief, 0-10 µl Hamilton syringe needle (Hamilton Microliter #701, Hamilton, Switzerland) was inserted through the skin into the infraorbital foramen, which lies in the medial part of zygomatic process, and through the infraorbital canal and foramen rotundum directly into the trigeminal ganglion. Saline-diluted BTX-A (1 U/kg, 2 µl) was slowly injected into the ganglion. Dose of 1 U/kg was chosen based on preliminary experiments and on the dose needed for antinociceptive effect after intrathecal application (Bach-Rojecky et al., 2010) . Site of injection was verified by injecting 2 µl of methylene blue (Sigma, St. Louis, MO, USA) to 5 animals. The dye resided only in trigeminal ganglion.
Behavioral testing
Antinociceptive activity of BTX-A was assessed in a model of formalin-induced facial pain.
Conscious rats were injected with 50 µl of saline-diluted 2.5% formalin (Kemika, Zagreb, Croatia) (0.92 % formaldehyde) into the whisker pad ipsilateral to BTX-A pretreatment and placed in transparent cages for observation (45 min). Observer was blind to the animal treatment (however, experienced observer could see slightly atonic rat whisker movement in BTX-A peripherally treated animals). The number of seconds of formalin-induced ipsilateral facial rubbing/grooming was measured in 3 min periods during phases I and II of formalininduced pain (Rabboison and Dallel, 2004) . Phase I (0-12 min) represents the acute nociceptive pain characterized by direct stimulation of nerve endings with formalin, while phase II (12-45 min) is characterized by the release of inflammatory mediators and sensitization (Cui et al., 2004, Raboisson and Dallel, 2004 ).
-For testing of peripherally applied BTX-A (3.5 U/kg), rats were divided in 3 groups (5-6 animals per group): 1. saline (i.g) + saline peripherally, 2. saline (i.g.) + BTX-A peripherally, 3. colchicine (i.g.) + BTX-A peripherally. Colchicine (Sigma, St. Louis, MO, USA) was injected i.g. (2 µl), as described above, 24 h prior to second injection (BTX-A or saline), ipsilaterally. To reduce the number of animals used, effects of intraganglionic colchicine (colchicine + saline group) on formalin-induced pain were tested only in the experiment with intraganglionic BTX-A application. Rats were tested 3 days after peripheral BTX-A injection based on data of Antonucci et al. (2008) and our preliminary experiments, and 1 and 2 days after intraganglionic BTX-A injection.
Characterization of the antibody specificity to BTX-A-cleaved SNAP-25 by Western blot
The antibody used for immunohistochemical detection of BTX-A-cleaved SNAP-25 (a kind gift from Assist. Prof. Ornella Rossetto, University of Padua, Italy) was used previously in study from Antonucci et al. (2008) . One of the questions to the authors, regarding the specificity of the antibody to cleaved SNAP-25, is the lack of controls to differentiate between cleaved and non-cleaved SNAP-25. Thus, using the similar protocol as Antonucci et al. (2008) , we injected BTX-A (4 U/rat) in rat dorsal hippocampus. One day following the treatment rats were sacrificed and hippocampus excised. Protein isolation, SDS-PAGE and Western blots were performed as described previously (Antonucci et al., 2008 , Constantin et al., 2005 . To visualize cleaved SNAP-25, and then the total SNAP-25, two sequential Western blots were performed on the same membrane. Membranes were blocked and incubated firstly with rabbit anti-cleaved SNAP-25 (1:500) in blocking solution overnight at 4°C, and then with goat-anti-rabbit HRP -conjugated secondary antibody (Biosource, Invitrogen, Carlsbad, CA, USA). After development in chemoluminescent (Super Signal West Femto, Pierce, Rockford,IL, USA) and visualization by ECL camera (Biorad, Hercules, CA, USA), membrane was washed and incubated with the mouse monoclonal antibody to total SNAP-25 (1:5000, overnight at 4°C). Antibody to total SNAP-25 (SMI-81, Sternberger
Monoclonals, Baltimore, MD, USA) is well characterized and recognizes both intact and BTX-A-cleaved SNAP-25 (Jurasinski et al., 2001) . Then, the membrane was incubated with goat anti-mouse secondary antibody (BD Pharmingen, San Diego, CA, USA) and visualized. Figure 1
Immunohistochemistry
For the time-course experiment rats were injected into the whisker pad with 15 U/kg BTX-A, and sacrificed 1, 3, or 5 days after BTX-A injection. To access the BTX-A effects at different peripheral doses, rats were injected with 3.5 U/kg, 15 U/kg, and 30 U/kg into the whisker pad and sacrificed after 5 days. Doses were chosen based on study from Cui et al. (2004) . Rats were deeply anesthetized using chloral hydrate (300 mg/kg, i.p.) and transcardially perfused with 250 ml saline, followed by 250 ml of fixative (4% paraformaldehyde (Sigma-Aldrich, St.
Louis, MO, USA) in 0.01 M PBS, pH 7.4). Brainstems with upper cervical spinal cords were dissected and cryoprotected at 4ºC overnight in 15% sucrose in fixative, followed by 30 % sucrose in PBS the next day, until the tissue sank. Immunohistochemical protocol was similar to that previously described (Antonucci et al., 2008) . To obtain high-resolution image of the whole section, parts of brainstem sections were photographed using 10x magnification, and subsequently connected using Microsoft Paint software. Images were processed for brightness and contrast using Adobe Photoshop software.
Statistical analysis
The results of orofacial formalin test were presented as mean ± S.E.M. Between-group differences were analyzed by the Newman-Keuls post hoc test. P<0.05 was considered significant. 5) . Occurrence of truncated SNAP-25 in dorsal horn was evident starting on day 3 after the injection but not on day 1 (Figure 5 A) . Truncated SNAP-25 in TNC also appeared at lower and higher peripheral doses (3.5 and 30 U/kg) ( Figure 5B ). We did not quantify the immunoreactivity, however, our impression was that 3.5 U/kg dose produces less intensive cleaved SNAP-25 immununofluorescence than higher doses (15 U/kg and 30 U/kg).
RESULTS
BTX-
Cleaved SNAP-25 was present throughout the rostro-caudal length of the TNC and confined to the middle part of the medullar dorsal horn coronal section (TNC according to rat brain atlas (Paxinos and Watson, 2005) ). This is in accordance with the dorso-ventral somatotopic organization of spinal trigeminal nuclei, whose middle portion belongs to maxillary branch of trigeminal nerve, which innervates the whisker pad (Florence and Lakshman, 1995; Capra and Dessem, 1992) . In some sections only few immunoreactive fiber-like structures were visible in contralateral dorsal horn. Some immunoreactivity was also observed inconsistently in C1
upper cervical dorsal horn. Analogous mechanism was proposed as an explanation of antinociceptive activity in peripheral sensory neurons (Cui et al., 2004; Aoki, 2005) . In formalin-induced inflammatory pain, peripheral BTX-A pretreatment had no effect on the acute nociceptive pain in phase I but it reduced pain during inflammatory phase II, accompanied by lowered peripheral glutamate release and reduction of edema in inflamed paw tissue. The most logical explanation was that both antinociceptive and anti-inflammatory actions of BTX-A are mediated by blockage of neurotransmitter and inflammatory mediator release from sensory nerve endings, as a consequence of peripheral SNAP-25 cleavage (Aoki, 2005) .
However, further studies with other inflammatory pain models showed dissociation between anti-inflammatory and antinociceptive activity of BTX-A. When applied in doses that effectively reduced pain, BTX-A had no effect on capsaicin-induced neurogenic inflammation within ganglionic somata, we investigated whether BTX-A antinociceptive activity is caused by its actions inside the ganglion. We speculated that direct i.g. delivery of BTX-A would cause the spread of toxin within the ganglion and should enable fast antinociceptive effect.
However, in the present experiment this action was delayed, occurring after 2 days, opening the possibility that the ganglion itself is not the main site of BTX-A antinociceptive activity.
Moreover, by blocking axonal transport with colchicine pretreatment, effect of intraganglionic BTX-A was prevented (Figure 3 ), suggesting that BTX-A, even when delivered directly to the ganglion, still requires axonal transport to exert its antinociceptive effects. Thus, we hypothesized that BTX-A could be axonally transported, via sensory root, to trigeminal nociceptive projections in central nervous system.
Occurrence of truncated SNAP -25 in the CNS after BTX-A injection in trigeminal innervation area
To verify our assumption about the axonal transport of peripherally applied BTX-A to central trigeminal projections, we employed immunohistochemical labeling of truncated SNAP-25 in trigeminal nucleus caudalis (TNC), the region that predominantly receives facial nociceptive input. By demonstrating SNAP-25 cleavage in TNC we found that peripherally applied BTX-A, or its catalytically active fragments, most probably reach central projections of primary sensory neurons by axonal transport (Figures 4 and 5) . Time of occurrence of truncated SNAP-25 in our experiment ( Figure 5A ) is similar to the time course of BTX-A traffic in central neurons and motoneurons (Antonucci et al., 2008 ).
Theoretically it might be possible that, instead of BTX-A, the truncated SNAP 25-product of its proteolytic activity, was axonally transported to central trigeminal nuclei. However, previously it was shown that BTX-A injection into the sciatic nerve, which was cut distally to the place of toxin's injection, still reduces pain on contralateral side (Bach-Rojecky and Lacković, 2009 ). This experiment rules out the possibility that cleaved SNAP-25, transported from peripheral nerve endings, would be involved in antinociceptive effects of BTX-A.
Possibility of contribution of SNAP-25 cleavage in trigeminal ganglion cannot be ruled out completely.
Confinement of cleaved SNAP-25 immunoreactivity to medullary dorsal horn excludes possible systemic spreading of BTX-A. Moreover, animals injected into whisker pad with 3.5
and 15 U/kg did not exhibit impaired rotarod performance (results not shown). However, in some sections, few immunoreactive fiber-like structures were also visible in contralateral dorsal horns (data not shown), which could be associated with contralateral crossing of central afferent terminals (Jacquin et al., 1990) .
Occurrence of truncated SNAP-25 in TNC suggest that peripherally applied, axonally (Meng et al., 2009; Lee et al., 2010) .
Importantly, we found that BTX-A-truncated SNAP-25 appeared in TNC even at 3.5 U/kg, the lowest peripheral antinociceptive dose . Therefore, the axonal traffic of BTX-A from periphery to the CNS is not a phenomenon occurring only at high doses, as proposed by Alexiades -Armenakas (2008) .
Although comparison of doses in rats and humans can always be questioned, dose used in our experiment (3.5 U/kg) corresponds to 245 U dose in 70 kg human. BTX-A doses typically used in migraine treatment range from 100 to 260 U (Aurora et al., 2007) , and in recent study which resulted in FDA approval for migraine treatment, from 155 to 195 U (Dodick et al., 2010) .
Conclusion
Antinociceptive effect of BTX-A requires axonal transport through sensory neurons and it is associated with occurrence of truncated SNAP-25 in central sensory nociceptive nuclei. Sections approx. 1-1.5 mm caudal from obex. 40 x magnification; scale bar (gray line), 100
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